FUAS for Adenomyosis: High Symptom Relief, Low Major Adverse Events, but 45% Long-term Recurrence

FUAS monotherapy for adenomyosis: pooled dysmenorrhea remission 79% (95% CI 75-83%), major adverse events 0.3%, but long-term recurrence 45% in meta-analysis of 27 studies (13,307 pts).

• Systematic review and meta-analysis of 27 observational studies involving 13,307 patients; no randomized controlled trials available.
• Menorrhagia remission rate 75% (95% CI 69-81%), and female sexual function index increased by 5.38 points (95% CI 2.77-8.00).
• Limitations: predominantly single-arm retrospective studies, procedure not yet approved by major regulatory bodies, and high long-term recurrence rate (45%).

RadPigeon summaries are original and for information only. They are not clinical advice.